Vanguard Group Inc. Buys 386,499 Shares of Clover Health Investments, Corp. (NASDAQ:CLOV)

Vanguard Group Inc. boosted its position in Clover Health Investments, Corp. (NASDAQ:CLOV - Free Report) by 2.0% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 19,585,213 shares of the company's stock after purchasing an additional 386,499 shares during the period. Vanguard Group Inc. owned about 3.91% of Clover Health Investments worth $61,693,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in shares of Clover Health Investments during the 3rd quarter worth approximately $1,228,000. Verition Fund Management LLC acquired a new stake in Clover Health Investments during the 3rd quarter valued at $411,000. HighTower Advisors LLC bought a new position in Clover Health Investments during the third quarter worth $97,000. Janus Henderson Group PLC acquired a new stake in shares of Clover Health Investments during the 3rd quarter worth about $477,000. Finally, State Street Corp grew its stake in Clover Health Investments by 65.0% in the 3rd quarter. State Street Corp now owns 2,189,380 shares of the company's stock valued at $6,174,000 after buying an additional 862,621 shares during the last quarter. Institutional investors and hedge funds own 19.77% of the company's stock.

Insider Transactions at Clover Health Investments

In other news, General Counsel Karen Soares sold 52,500 shares of the company's stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $3.80, for a total transaction of $199,500.00. Following the completion of the sale, the general counsel now owns 1,299,663 shares of the company's stock, valued at approximately $4,938,719.40. This represents a 3.88 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Carladenise Armbrister Edwards sold 200,000 shares of the business's stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $3.61, for a total transaction of $722,000.00. Following the transaction, the director now owns 273,227 shares of the company's stock, valued at approximately $986,349.47. This represents a 42.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 327,500 shares of company stock valued at $1,197,500. 22.28% of the stock is currently owned by company insiders.

Clover Health Investments Stock Performance

Shares of CLOV stock traded down $0.10 on Thursday, hitting $3.60. The company's stock had a trading volume of 813,960 shares, compared to its average volume of 6,116,303. Clover Health Investments, Corp. has a fifty-two week low of $0.61 and a fifty-two week high of $4.87. The company has a market capitalization of $1.84 billion, a PE ratio of -17.97 and a beta of 1.98. The stock's 50 day moving average is $3.84 and its 200-day moving average is $3.75.

Analyst Upgrades and Downgrades

Separately, Canaccord Genuity Group boosted their price objective on Clover Health Investments from $4.20 to $4.50 and gave the stock a "buy" rating in a report on Monday, March 3rd.

Clover Health Investments Profile

Clover Health Investments, Corp. provides medicare advantage plans in the United States. It operates through two segments: Insurance and Non-Insurance. It also offers Clover Assistant, a cloud-based software platform, that enables physicians to detect, identify, and manage chronic diseases earlier; and access to data-driven and personalized insights for the patients they treat.